心律不全とに関連したナトリウムチャネル機能障害を逆転させるペプチド調節器の新規設計

関連する実験動画

Updated: Sep 10, 2025

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

Ryan Mahling¹, Bence Hegyi², Erin R Cullen³

¹Department of Physiology and Cellular Biophysics, Columbia University, New York, NY, USA.

|August 19, 2025

まとめ

新しいペプチドであるELIXIRを設計し,電圧ゲートされたナトリウムチャネル (Na_V) で病原性の遅いナトリウム電流 (I_NaL) を正確に標的と抑制しました. この合成調節器は心律不全やなどの治療に有望です

科学分野:

バイオ物理学
分子生物学
コンピュータ生物学

背景:

イオンチャネルは刺激性細胞の電気信号伝達に不可欠です
イオンチャネル機能の調節は生理学的プロセスに不可欠である.
ボルトゲートナトリウムチャネル (Na_V) の機能不全により,遅い/持続的なナトリウム電流 (I_NaL) が増加すると,心律不整症と症に関連している.

研究の目的:

イオンチャネルの機能を正確に調整するための合成ペプチド変調器を設計する.
Na_Vチャネルにおける病原性遅ナトリウム流 (I_NaL) の選択的阻害剤を開発する.
イオンチャネル調節器の治療の可能性を探るため

主な方法:

新しいペプチドを設計するために計算型タンパク質設計プラットフォームを利用した
Na_Vチャネルを標的にするために,不活性化ゲートリリースによる遅い電流阻害剤X (ELIXIR) を設計した.
細胞とネズミのモデルを用いて結合親和性と機能的効果を評価した.

主要な成果:

エンジニアリングされたELIXIRペプチドはNa_Vチャネルをサブミクロモラアフィニティで結合する.
ELIXIRは病原性I_NaLを選択的に抑制することが示されました.
臨床前モデルでは,心律不全とに関連したNa_V機能障害を効果的に逆転させました.

結論:

合成イオンチャネル調節器を作るための実行可能な戦略です.
ELIXIRは,Na_Vチャネル病変に対する標的治療の開発に有望な先駆けとなります.
この研究は,イオンチャネル活動を調節する将来の治療法の合理的な設計のための道を開きます.

キーワード:

LQT3 について心臓発作 de novo タンパク質のデザインエピレプシーイオンチャネル病変イオンチャネル遅いナトリウム流ナトリウムチャネル病ナトリウムチャネル合成モジュール

さらに関連する動画

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate

Published on: July 10, 2018

関連する概念動画

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...

Antiepileptic Drugs: Calcium Channel Blockers

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...